New Clinical Endocrinology Guidelines Support Lp-PLA2 Measurement For Risk Assessment of Coronary Artery Disease

SOUTH SAN FRANCISCO, Calif., April 26, 2012 /PRNewswire/ -- diaDexus, Inc. (OTC Bulletin Board: DDXS), a company focused on the development and commercialization of proprietary cardiovascular diagnostic products, today announced the inclusion of its vascular-specific inflammatory marker Lp-PLA2 in the American Association of Clinical Endocrinologists ("AACE") medical guidelines for clinical practice published in the March/April 2012 issue of Endocrine Practice . "The AACE's guidelines are an i...continued DDXS

URL: http://www.investorpoint.com/news/OTCBULLB/50708283/